Rheumatology CRO Services

Tell us about your study

We’ll connect you with the right rheumatology development team.

Complex Rheumatology Trials Require Connected Expertise

We combine deep therapeutic insight with operational continuity, designing eligibility criteria that reflect real-world patients, optimizing biomarker strategies before recruitment begins, and maintaining expertise and rater consistency throughout long study lifecycles. The result is lower enrollment risk, fewer operational surprises, and greater confidence in clinical development decisions.

Biomarker Eligibility & Screen Failure

Stringent biomarker cutoffs can limit the recruitable patient pool, misalign enrollment projections with real-world availability, and expose feasibility challenges only after screening begins.

Eligibility That Doesn’t Match Clinical Practice

Eligibility criteria built around an idealized patient can conflict with real-world rheumatology practice, increasing protocol amendments, screening costs, and timeline delays that stronger upfront protocol scrutiny could prevent.

Rater Consistency Over Long Trials

Many rheumatology endpoints rely on subjective clinical assessments, making rater consistency critical. Long studies increase the risk of scoring drift, site variability, and knowledge loss as personnel change. Ongoing training, recalibration, and centralized review help maintain accurate, reproducible assessments.

The Team You Meet at Bid Defense Is the Team That Delivers Your Program

We believe long studies deserve long-term commitment. From bid defense to database lock, the same scientific, medical, and operational leaders stay accountable for your program’s success. Our CRA turnover rate of just 9.5%, compared with an industry norm closer to 25%, helps preserve expertise, site engagement, and operational consistency throughout delivery. Combined with a flat, empowered organizational structure, this means issues are resolved faster, decisions happen closer to the study, and studies are kept on track.

What Worldwide’s Rheumatology Programs Have Delivered

With experience spanning 75 autoimmune studies over the last five years, we bring the expertise and operational discipline required to keep programs on schedule and critical development decisions on track.

7-Point Drop in Screen Failure Rate for Faster Enrolment

Senior scientific and medical reviewers built a registry of trial-ready eligible patients on a Global Phase II autoimmune study, delivering a 7 percentage point reduction in global screen failure rate.

Concurrent Site Startup & Enrollment Across 3 Global Studies

Three consecutive global Phase II autoimmune programs delivered last patient in ahead of schedule with site identification and enrollment running concurrently.

Proven Delivery at Global Phase II-III Autoimmune Studies

Five years of late-stage delivery and 53 autoimmune studies at global Phase II or III for IBD, rheumatology, lupus, and rare systemic indications.

Reduced Risk, Starting at Protocol Design

Autoimmune Thought Leadership & Biomarker Precision

The scientific leaders who authored our April 2026 white paper on recruitment optimization and biomarker precision apply the same expertise to every study we support, translating best practice into eligibility strategies that improve feasibility, reduce enrollment risk, and accelerate execution.

Adaptive Design for Rare Systemic Indications

Basket, umbrella, and adaptive design capability for rare systemic autoimmune programs where standard eligibility and enrollment models do not fit the patient population.

Phase I–III Delivery Through Trusted Partners

From first‑in‑human through Phase III, we support SAD/MAD designs and biomarker‑driven patient stratification. Established clinical pharmacology units and bioanalytical labs are matched to each program’s needs, so one team runs your study through every phase.

Your Questions Answered

We have answered the questions sponsors ask most often about rheumatology programs. If yours isn’t here, our autoimmune team is happy to help.

Senior scientific and medical reviewers rigorously assess eligibility criteria, biomarker thresholds, and enrollment assumptions against current clinical practice before protocol finalization. In rheumatology, many of the factors that ultimately drive amendments are introduced at the design stage, making early scrutiny one of the most effective ways to reduce risk for our sponsors.

Yes. 53 of our 75 autoimmune studies over the past five years were global Phase II or Phase III, including programs spanning 20 countries and 102 sites – all delivered ahead of schedule.

Biomarker eligibility is set against how patients present in the clinic, not against an idealized profile. Where the thresholds sit determines who screens in, which is why we test them before activation rather than after. The April 2026 white paper, Optimizing Recruitment and Biomarker Precision in Autoimmune and Rare Autoimmune Trials, sets out the approach in full.

Composite rheumatology endpoints such as DAS28-CRP and ACR20/50/70 depend on rater consistency across sites and across time. We train to a single standard, monitor for rater drift through continuous data surveillance and remediate early rather than at database lock. On a global Phase III rheumatoid arthritis program, submission-ready endpoint data was accepted by the FDA, PMDA and EMA, with eCOA go-live accelerated by around two months across 5,000 endpoint visits.

Rheumatology protocols ask a great deal of patients: frequent visits, invasive assessments and long maintenance periods during which many of them feel well. We plan for that at design stage rather than at rescue stage, with flexible ePRO capture, home health for off-site labs, and visit windows built against real travel and work constraints.